NCT06402214

Brief Summary

Adductory spasmodic dysphonia (AdSD) is a rare condition characterised by irregular and uncontrolled voice interruptions, most commonly affecting women around the age of 45. The diagnosis is clinical and usually requires evaluation by several specialists. The exact cause is not known, but a disturbance of the motor system is hypothesised, probably related to various causes such as loss of cortical inhibition or problems with sensory input. Neuroimaging studies have shown hyperactivity in various brain regions during speech production in patients with AdSD, but it is still unclear whether this hyperactivity is due to a malfunction of auditory and somatosensory feedback or an impairment of motor programming. Recent research indicates that patients with AdSD show excessive muscle activation during phonation, probably due to abnormal processing of auditory feedback. This suggests that intervention in the auditory system may offer new treatment opportunities. The proposed study aims to describe the acoustic, auditory-perceptual and subjective voice and speech changes in AdSD subjects during the Quick-Lombard Test (LT), a test that assesses vocal response under noisy conditions.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
18

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2024

Completed
12 days until next milestone

Study Start

First participant enrolled

May 1, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 7, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2025

Completed
Last Updated

May 7, 2024

Status Verified

April 1, 2024

Enrollment Period

12 months

First QC Date

April 19, 2024

Last Update Submit

May 2, 2024

Conditions

Keywords

laryngeal dystoniaspasmodic dysphoniaLombard effectauditory system

Outcome Measures

Primary Outcomes (9)

  • OMNI Vocal Effort Scale

    It is a validated instrument for the assessment of vocal effort perceived by the patient with AdSD. The OMNI-VES is a visual analogue scale 0-10 with graphic representation of vocal effort. The OMNI-VES will be administered under silent conditions and after the LT

    At the time of enrollement

  • Auditory-perceptual assessment

    Blinded perceptual assessment, using the Global Grading Scale - Hoarseness - Straining - Asthenia - Straining (GRBAS) 0-3 (0 = normal; 1 = mild; 2 = moderate; 3 = severe) will be performed on the recorded voice samples by two speech therapists who will not be involved in the patients' care. Each voice sample will be anonymised and randomly distributed to the assessors.

    At the time of enrollement

  • Maximum Phonation Time

    The maximum phonatory time (TMF) will be obtained by asking the subject to sustain the vowel /a/ as long as possible in one breath. The longest of the three attempts will be calculated as TMF in seconds. The TMF will be obtained before and during LT.

    at the time of enrollement

  • Average Frequency (Hz)

    The Average Frequency is the fundamental frequency of the voice (pitch) usually ranges from approximately 30-300 Hz, but this varies according to different speakers: typically males' pitch ranges from 50-180Hz and females from 80-250Hz, so we usually set the pitch range to a reasonable range of 50-400Hz for general usage

    At the time of enrollement

  • Maximum Frequency (Hz)

    The Maximum Frequency (Hz) is the highest frequency recorded within the voice signal

    At the time of enrollement

  • Maximum Intensity (dB SPL)

    The Maximum Intensity (dB SPL) parameter refers to the highest intensity of the recorded voice signal

    At the time of enrollement

  • Degree of Voice Interruptions (%)

    Degree of Voice Interruptions (%) is useful for the evaluation of temporary vocal interruption

    At the time of enrollement

  • Cepstral Peak Prominence-Smoothed (CPPS)

    Cepstral Peak Prominence-Smoothed (CPPS) has been defined as a spectrum of a spectrum, whereby an inverse Fast Fourier Transform of the natural log of a frequency-domain spectrum is applied, transforming the spectrum to the time domain. The cepstral peak (CP) is a representation of the most dominant peak in the cepstrum - normally the fundamental frequency (fo) in a type I signal. After its first applications to voice was established the method of normalizing the amplitude of the overall cepstrum using a linear regression line. When applied to the cepstrum, the level difference (dB) between the cepstral peak and the regression line at the same quefrency provides the cepstral peak prominence (CPP). The CPPS values obtained from speech and vowel tasks proved reliable in predicting overall grade of dysphonia as well as breathiness.

    At the time of enrollement

  • Number of Voice Interruptions

    Number of Voice Interruptions is useful for the evaluation of temporary vocal interruption

    At the time of enrollement

Study Arms (2)

Case group

EXPERIMENTAL

patients affected by adductor laryngeal dystonia

Other: Lombard test

Control group

ACTIVE COMPARATOR

healthy patients

Other: Lombard test

Interventions

In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.

Case groupControl group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Native Italian-speaking patients;
  • Normal hearing, hearing threshold \< 20 dB HL for frequencies from 0.5 to 4 KHz;
  • Age \>18 years and \<65 years;
  • Written informed consent.

You may not qualify if:

  • Non-Italian-speaking patients.
  • Patients undergoing treatment for dystonia.
  • Previous laryngeal surgery.
  • Patient undergoing speech therapy.
  • Patient undergoing dopaminergic therapy.
  • Inability to sustain phonation of sufficient duration \>3 seconds or to perform sufficient tests to assess vocal outcomes.
  • Lack of written informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, 00168, Italy

Location

MeSH Terms

Conditions

Dysphonia

Condition Hierarchy (Ancestors)

Voice DisordersLaryngeal DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Maria Raffaella Marchese

    Fondazione Policlinico Universitario A. Gemelli, IRCCS

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maria Raffaella Marchese, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 19, 2024

First Posted

May 7, 2024

Study Start

May 1, 2024

Primary Completion

April 30, 2025

Study Completion

May 1, 2025

Last Updated

May 7, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

The data are paper-based

Locations